Jefferies stays Buy on Kalvista Pharmaceuticals Inc (KALV) after FY25 results

Jefferies analyst Maury Raycroft reiterated a Buy rating and $38.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV)

The analyst commented, "KALV reported FY25 results, w/ $49.1M global Ekterly revenue in line w/ prelim updates (here), and 1,702 total U.S. PSFs through 2/28/26 (vs 1,318 PSFs through 12/31/25). Mgmt expects consistent linear growth for 2026, while being cautious on pot'l (-)ve seasonal impacts on 1Q. Ekterly's strong launch progress is validating the thesis that HAE pts will use more on-demand drug & treat more attacks due to oral convenience. BUY w/ PT $38."

For an analyst ratings summary and ratings history on Kalvista Pharmaceuticals Inc click here. For more ratings news on Kalvista Pharmaceuticals Inc click here.

Shares of Kalvista Pharmaceuticals Inc closed at $16.46 yesterday.

You May Also Be Interested In

• Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027'
• UBS Reiterates Neutral Rating on CBOE Holdings (CBOE) Following June Metrics Release
• Replimune (REPL) call put ratio 1 call to 1.3 puts with a focus on August options